By Christopher Morrison
Glycobiology's Second Wave
New technologies to characterize and manipulate carbohydrate chemistries and the glycosylation of proteins are spawning viable business models that address what scientists have long known: the sugar coating of proteins and cells is not decorative.
More from Strategy
More from Business
• By
The AstraZeneca CEO again calls for rich European countries to pay more for new drugs because "a model where the US funds innovation in our industry for the entire world doesn't work."
• By
The AKT inhibitor proves ineffective for metastatic castration-resistant disease in a Phase III trial.
• By
First-quarter results season featured tariff talk but without any full-year quantitation. As tariffs and foreign exchange movements bump up against capped drug prices, profitability could suffer.